Weight Loss

Olaparib produced by Beacon (generic name: Olaparib; brand names: Lynparza, Lipuzhuo) is a PARP inhibitor originally developed by AstraZeneca. It has been approved by the FDA for the treatment of various cancers, including ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer.

It works by inhibiting DNA repair enzymes, preventing cancer cells from repairing their DNA, which leads to cell death and helps delay or stop tumor progression.

Beacon Pharmaceuticals was founded in 2001 and is one of the largest and most technologically advanced manufacturers of oncology and antiviral drugs in Bangladesh. Its products comply with international GMP certifications, including those from the US FDA, UK MHRA, and Australia’s TGA.